Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Microenvironment and Nephrectomy After Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell Renal Carcinomas, Including SMARCB1-Deficient Renal Medullary Carcinoma: The MANTIS-RCC Phase II Study

NCT07816770 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07816770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07816770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Microenvironment and Nephrectomy After Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell Renal Carcinomas, Including SMARCB1-Deficient Renal Medullary Carcinoma: The MANTIS-RCC Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 20, 2026
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-clear cell renal cell carcinoma, metastatic renal medullary carcinomas